Science & Enterprise subscription

Follow us on Twitter

  • A biotechnology company is sponsoring university research on light waves reacting in characteristic patterns for de…
    about 17 hours ago
  • New post on Science and Enterprise: Univ Lab, Company Developing Phone-Based Virus Sensor #Science #Business
    about 17 hours ago
  • A blood test designed for low-resource field settings is shown to quickly detect and distinguish between different…
    about 23 hours ago
  • New post on Science and Enterprise: Quick Crispr-Based Test Detects Malaria in Blood #Science #Business
    about 23 hours ago
  • Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulate…
    about 2 days ago

Please share Science & Enterprise

Vaccine Developer Awarded Countermeasures Center Contract

Vaccination (U.S. Army Corps of Engineers)

(U.S. Army Corps of Engineers)

Emergent BioSolutions Inc. in Rockville, Maryland was awarded a contract from Biomedical Advanced Research and Development Authority (BARDA) to establish a development center for medical countermeasures against public health emergencies. BARDA is a division of the U.S. Department of Health and Human Services (HHS). The eight-year contract is valued at $220 million.

The agreement will create a Center for Innovation in Advanced Development and Manufacturing for chemical, biological, radiological, and nuclear medical countermeasures. A key part of the program is to provide manufacturing capacity to meet the needs of a domestic influenza pandemic, including construction and workforce training.

Under the agreement, Emergent BioSolutions will find a suitable pandemic influenza vaccine candidate and obtain the intellectual property rights for its development and production. The company will construct any additional facilities for production of the pandemic influenza vaccine, including all of the licenses needed to manufacture the vaccine at a company facility in Baltimore.

The agreement will enable BARDA to call on Emergent BioSolutions to provide development and manufacturing services to other commercial partners under contract for drugs used against chemical, biological, radiological, and nuclear medical threats other than pandemic flu viruses. The agreement also calls for the company to develop workforce training programs to produce medical countermeasures.

The initial contract runs for eight years, but allows for additional one-year extensions for up to 17 more years.

Read more:

*     *     *

1 comment to Vaccine Developer Awarded Countermeasures Center Contract